Jenscare Scientific Co., Ltd. (9877.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.

Industry: Medical - Specialties
Sector: Healthcare
Headquarters: CN
CEO: Fei Pan
Listed since: Oct 10, 2022
Employees: 195

Market position

Day range

Current HK$7.345

HK$7.20HK$7.45

52-week range

Current HK$7.345

HK$6.00HK$11.98

Open: HK$7.45
Previous close: HK$7.49
Volume: 2.6K; 0.02× average
Average volume: 148.26K; Average daily volume
Market cap: 3.06B HKD
Beta: 0.65; Market reference 1
50-day average: HK$7.3568; -0.16% below average
200-day average: HK$8.4772; -13.36% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -14.31×
P/B (TTM): 3.44×
P/S (TTM): 31.81×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 80.52%
Operating margin: -191.76%
Net margin: -223.70%

Financial health

Debt / equity: 0.06×

Financial statements

Income trends

Operating income

−224M HKD-106152.06%

Net income

−264.21M HKD-148741.92%

Metric (HKD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	88.24M HKD	—	—	—	—
Cost of goods sold	21.64M HKD	—	—	—	—
Gross profit	66.6M HKD	—	—	—	—
Research and development	173.25M HKD	142.64K HKD	288.15M HKD	291.58M HKD	265.34M HKD
Selling, general, and administrative	53.41M HKD	68.18K HKD	150.31M HKD	49.62M HKD	38.53M HKD
Operating expenses	290.6M HKD	210.82K HKD	438.46M HKD	511.28M HKD	503.2M HKD
Interest income	13.46M HKD	11.25M HKD	19.18M HKD	8.36M HKD	1.77M HKD
Interest expense	844.56K HKD	289K HKD	—	113K HKD	130K HKD
Depreciation and amortization	13.78M HKD	8.78K HKD	8.78M HKD	6.46M HKD	3.41M HKD
Operating income	−224M HKD	−210.82K HKD	−438.46M HKD	−511.28M HKD	−503.84M HKD
Net income	−264.21M HKD	−177.51K HKD	−371.74M HKD	−439.31M HKD	−500.52M HKD